Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Date:7/14/2009

---- ---- LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $3,518,000 $2,060,000 Accrued clinical trial site fees 955,000 237,000 Accrued legal and accounting fees 667,000 450,000 Accrued royalties and license fees 182,000 222,000 Accrued payroll and related costs 1,580,000 1,084,000 Capital lease obligation, current portion 17,000 22,000 Notes payable, current portion and net of discount 1,465,000 - Deferred revenue 3,776,000 2,196,000 Deferred government contract revenue 3,871,000 - Customer deposits 2,287,000 838,000 Other current liabilities 546,000 331,000 ------- ------- Total current liabilities 18,864,000 7,440,000 Capital lease obligation, less current portion 4,000 22,000 Notes payable, less current portion and net of discount 3,208,000 - Other long-term liabilities 150,000 - Commitments and contingencies STOCKHOLDERS' EQUITY: Preferred stock - $.001 par value; authorized 5,000,000 shares; non-voting; nil shares outstanding - - Common stock - $.001 par value; authorized 325,000,000 shares; outstanding - 227,688,555 and 226,210,617, respectively 227,000 226,000 Additional paid-in-capital 248,034,000 246,205,000 Accumulated deficit
'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... HealthDay Reporter THURSDAY, Aug. ... in treating respiratory syncytial virus (RSV), a leading cause of ... major progress in being able to treat human RSV infections ... second only to influenza virus," said study author Dr. John ... College of Medicine in Memphis. "There is no ...
(Date:8/21/2014)... According to the new report “Waterborne Coatings ... PTFE, PVDF, PVDC, & Others), by Application (Architectural, ... & Others) - Global Forecast to 2019” published ... estimated to reach $77,838.71 Million by 2019. , ... spread through 225 Slides and in-depth TOC on ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 According to ... "Enteral Feeding Devices Market (Enteral Feeding Tubes, Enteral Feeding ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast,2013 ... valued at USD 2.0 billion in 2012 and is ... billion in 2019growing at a CAGR of 6.2% from ...
(Date:8/21/2014)... polio is considered nearly eradicated. Each year only a ... the University of Bonn, together with colleagues from Gabon, ... able to resist the vaccine protection to a considerable ... the Congo in 2010. The pathogen could also potentially ... now in the magazine PNAS . , The ...
(Date:8/21/2014)... One of the emerging trends that the Intranasal ... increasing adoption of non-invasive administration products. As non-invasive nasal ... their convenient application, they find more preference among end-users. ... used for the administration of drugs for the treatment ... such as allergic and non-allergic rhinitis and sinusitis. The ...
Breaking Medicine News(10 mins):Health News:New Drug May Fight Serious Respiratory Virus in Infants 2Health News:New Drug May Fight Serious Respiratory Virus in Infants 3Health News:Waterborne Coatings Market worth $77,838.71 Million by 2019 – New Report by MarketsandMarkets 2Health News:Waterborne Coatings Market worth $77,838.71 Million by 2019 – New Report by MarketsandMarkets 3Health News:Waterborne Coatings Market worth $77,838.71 Million by 2019 – New Report by MarketsandMarkets 4Health News:Enteral Feeding Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Enteral Feeding Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Enteral Feeding Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Polio: Mutated virus breaches vaccine protection 2Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 2Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 3Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 4Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 5
... 24 NHS Choices ( http://www.nhs.uk ), the,digital ... well guide on women,s,health aged 18-39 aimed at ... lifestyle., Based on NHS accredited information, the ... with information about,walking to get healthy, looking after ...
... June 24 TransUnion announced today a ... cycle workflow and,financial analytics product suite -- ... Institute (ANI) Healthcare Financing Conference. Revenue,Manager is ... real time,patient eligibility for financial assistance at ...
... LOS ANGELES, June 24 Anti-Doping Research,Inc. (ADR), one ... performance-enhancing drugs in sport, is pleased to announce that ... "We,ve been up and running and fully-operational for a ... Officer of the organization. "But,now it,s all official and ...
... Inc. (Pink Sheets: AMHI), http://www.americanhealthchoice.com, a medical ... today, in an update for Company,shareholders, said its ... 31, 2008,totaled $32,300., Net income for the ... Company announced that patient billings from its four ...
... To, Implement Electronic Bill / Payment Solutions Before Minnesota,s ... ... and CONCORD, Calif., June 24 More than one,hundred auto insurance ... Mitchell Medical,s 2008 Industry,Conference held March 17-19 in Monterey, CA were ...
... in Generic Market Information Offers Newport Horizon ... ... SHANGHAI, China, June 24 /Xinhua-PRNewswire/ -- Thomson Reuters, the,world,s leading ... CPhI China 2008(1) the release of Newport,Horizon Premium, designed specifically ...
Cached Medicine News:Health News:TransUnion's Enhanced Revenue Manager(SM) Improves Patient Financial Assistance, Assessments and Hospital Productivity 2Health News:TransUnion's Enhanced Revenue Manager(SM) Improves Patient Financial Assistance, Assessments and Hospital Productivity 3Health News:TransUnion's Enhanced Revenue Manager(SM) Improves Patient Financial Assistance, Assessments and Hospital Productivity 4Health News:Leading Performance-Enhancing Drug Research Institute Anti-Doping Research (ADR) Establishes Nonprofit Status 2Health News:American HealthChoice CEO Dr. J.W. Stucki Provides Company Update 2Health News:2008 Mitchell Medical Industry Conference Previews 100 Percent Paperless Auto Medical Claim Solution 2Health News:2008 Mitchell Medical Industry Conference Previews 100 Percent Paperless Auto Medical Claim Solution 3Health News:2008 Mitchell Medical Industry Conference Previews 100 Percent Paperless Auto Medical Claim Solution 4Health News:Thomson Reuters Introduces a New Solution to Boost Competitive Advantage in China's Generics and API Market 2Health News:Thomson Reuters Introduces a New Solution to Boost Competitive Advantage in China's Generics and API Market 3
(Date:8/21/2014)... percent of Americans believe the abuse of strong prescription pain ... safety issue in the United States , ... & Partners, a Cincinnati based research ... the prescription medication abuse problem and the need for medical ... facing our country," Rex Repass , CEO of the ...
(Date:8/21/2014)... InfinityQS International, Inc., the global authority ... today announces Infusion Chicago, its 9 th ... Oct. 9-10, 2014, at the Chicago Marriott Downtown ... necessity for implementing a quality system that optimizes ... gain insight into production processes. Complimentary registrations are ...
(Date:8/21/2014)... 2014 Professional Compounding Centers of America ... awarding the three best scientific presentations at the ... . The Formulating Better Medicines for Children ... Athens, Greece , includes dozens of ... from which three winners will be selected by ...
Breaking Medicine Technology:Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2
... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ... Administration (FDA) has accepted for review the Company,s supplemental ... Use for the prevention of gout flares in patients ... Fee Act (PDUFA), the goal for a standard review ...
... CITY, Nev., Nov. 22, 2011   Denali Concrete Management ... November 21, 2011 of the reverse acquisition of Denali ... of which Denali acquired all the outstanding shares of ... has been granted from Can-Fite an exclusive license over ...
Cached Medicine Technology:Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 2Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 3Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 4Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 5Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 6Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 7Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 8Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share 2Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share 3
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. Depth: 550 to 700....
Designed to remove cell debris or tissue remnants from the retina....
... Medtronic presents the Streamline family of ... have taken the gold standard in temporary ... that make them easy to use and ... Model 6491 Unipolar Pediatric Temporary Pacing Lead ...
Lytec Medical 2004 practice management software is designed to help you more effectively manage your accounts receivable as well as track authorizations and inventory. Lytec Medical XE provides outst...
Medicine Products: